Amended Current Report Filing (8-k/a)
December 17 2021 - 3:26PM
Edgar (US Regulatory)
0001552189
true
0001552189
2021-12-17
2021-12-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form
8-K/A
Amendment
No 1
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 17, 2021
PANACEA
LIFE SCIENCES HOLDINGS, INC.
(Exact
name of the registrant as specified in its charter)
Nevada
|
|
001-38190
|
|
27-1085858
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
5910
South University Blvd, C18-193
Greenwood
Village, CO 80121
(Address
of principal executive offices) (Zip code)
Registrant’s
telephone number, including area code: 1-800-985-0515
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions (see General Instruction A.2 below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
symbol(s)
|
|
Name
of exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
This Current Report on Form 8-K/A (this “Amendment”)
is being filed by Panacea Life Sciences Holdings, Inc., a Nevada corporation (the “Company”), to amend its Current Report
on Form 8-K (the “Prior 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on July 7, 2021,
in connection with the consummation on June 30, 2021 of the exchange agreement between Panacea Life Sciences Holdings, Inc.(formerly
Exactus, Inc.) and Panacea Life Sciences, Inc.
The Company is filing this Amendment solely to provide (i) certain voluntary disclosures concerning the financial condition of the Company,
as permitted by Item 8.01; (ii) the historical audited financial statements of Panacea Life Sciences, Inc. as of and for the years ended
December 31, 2020 and 2019, and the unaudited condensed consolidated financial statements as of June 30, 2021 and 2020, referred to in
Item 9.01(a) below; and (iii) the unaudited pro forma condensed combined financial statements as of and for the six month period ended
June 30, 2021 and for the year ended December 31, 2020, referred to in Item 9.01(b) below.
Item
8.01 Other Events.
The
Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations as of December 31, 2020 and
audited condensed consolidated financial statements for the years ended December 31, 2020 and 2019, are filed herewith and attached hereto
as Exhibits 99.1 and incorporated herein by reference.
The
Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three months and
six months ending June 30, 2021 and the unaudited interim condensed consolidated financial statements for the six months ending
June 30, 2021 and 2020 filed are filed herewith and attached hereto as Exhibits 99.3 and incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(a)
Financial Statements of Business Acquired
The
audited financial statements of Panacea Life Sciences, Inc. as of and for the years ended December 31, 2020 and 2019 are filed herewith
attached here to in Exhibit 99.2.
(b)
Pro Forma Financial Information.
The
unaudited pro forma condensed combined financial statements of the Company and Panacea Life Sciences, Inc. as of and for the six month
period ended June 30, 2021 and for the year ended December 31, 2020, filed herewith and attached hereto as Exhibit 99.4.
(d)
Exhibits
Below
is a list of exhibits included with this Current Report on Form 8-K.
Exhibit
No.
|
|
Document
|
|
Filed
|
3.1
|
|
Amended Articles of Incorporation*
|
|
Filed
|
|
|
|
|
|
3.2
|
|
Amended Bylaws*
|
|
Filed
|
|
|
|
|
|
10.1
|
|
Form of Securities Exchange Agreement*
|
|
Filed
|
|
|
|
|
|
10.2
|
|
Form of Indemnification Agreement*
|
|
Filed
|
|
|
|
|
|
99.1
|
|
Audited consolidated financial statements of Panacea Life Sciences Holdings, Inc. (formerly Exactus, Inc.) for the fiscal years ended December 31, 2020 and 2019 including the report of RBSM LLP on such audited financial statements, filed with the Securities and Exchange Commission on April 23, 2021*
|
|
Filed
|
|
|
|
|
|
99.2
|
|
Audited financial statements of Panacea Life Sciences, Inc. for the years ended December 31, 2020 and 2019 including report of RBSM LLP on such audited financial statements filed.
|
|
Filed
herewith
|
|
|
|
|
|
99.3
|
|
Unaudited interim financial statements of Panacea Life Sciences Holdings, Inc. for the six months ending June 30, 2021 and 2020 filed on Form 10-Q/A with the Securities and Exchange Commission on December 17, 2021.*
|
|
Filed
|
|
|
|
|
|
99.4
|
|
Unaudited pro forma condensed combined financial statements of the Company and Panacea Life Sciences for the six month period ended June 30, 2021 and for the year ended December 31, 2020.
|
|
Filed
herewith
|
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
|
*
Previously filed with the Original Reports.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
December 17, 2021
|
|
|
|
/s/
Leslie Buttorff
|
|
Leslie
Buttorff
|
|
Chief
Executive Officer and Chief Financial Officer
|
|
(Principal
Executive Officer and Principal Financial Officer)
|
|
Panacea Life Sciences (PK) (USOTC:PLSH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Panacea Life Sciences (PK) (USOTC:PLSH)
Historical Stock Chart
From Jul 2023 to Jul 2024